trending Market Intelligence /marketintelligence/en/news-insights/trending/ct87iwk4okm_f_ge0qjgga2 content esgSubNav
In This List

ViiV Healthcare sues Gilead over HIV patent infringement

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


ViiV Healthcare sues Gilead over HIV patent infringement

ViiV Healthcare filed lawsuits in U.S. and Canada alleging patent infringement by Gilead Sciences Inc. for its newly approved HIV-1 treatment Biktarvy.

The company, majority owned by GlaxoSmithKline plc with Pfizer Inc. and Shionogi & Co. Ltd. as shareholders, said Biktarvy infringed patents on its HIV treatment dolutegravir, or Tivicay, and other compounds with the drug's "unique chemical scaffold," according to a news release.

The lawsuits come after the U.S. Food and Drug Administration approved Biktarvy, a once-daily single tablet regimen for treating HIV-1 infection.

The U.S. case was filed in the U.S. District Court for the District of Delaware. The Canadian case was filed in the Canadian Federal Court in Toronto.